Extended anticoagulation in provoked VTE with persistent risk factors: A meta-analysis of randomised trials
References
- White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):14–18. doi:10.1161/01.CIR.0000078468.11849.66. PubMed PMID: 12814979.
- Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol. 2023;20(4):248–262. doi:10.1038/s41569-022-00787-6.
- Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14(7):1480–1483. doi:10.1111/jth.13336.
- Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738. doi:10.1182/bloodadvances.2020001830.
- Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(4):543–603. doi:10.1093/eurheartj/ehz405.
- Khan F, Rahman A, Carrier M, Kearon C, Weitz JI, Schulman S, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: Systematic review and meta-analysis. BMJ. 2019;366:l4363. doi:10.1136/bmj.l4363. PubMed PMID: 31340984; PubMed Central PMCID: PMC6651066.
- Piazza G, Bikdeli B, Pandey AK, Krishnathasan D, Khairani CD, Bejjani A, et al. Apixaban for extended treatment of provoked venous thromboembolism. N Engl J Med. 2025;393(12):1166–1176. doi:10.1056/NEJMoa2509426. PubMed PMID: 40888734.
- Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211–1222. doi:10.1056/NEJMoa1700518. PubMed PMID: 28316279.
- Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv. 2018;2(7):788–796. doi:10.1182/bloodadvances.2018017160. PubMed PMID: 29632234; PubMed Central PMCID: PMC5894264.
- EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510. doi:10.1056/NEJMoa1007903.
- Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708. doi:10.1056/NEJMoa1207541. PubMed PMID: 23216615.
- Ibrahim A, Shalabi L, Zreigh S, Tawfik AM, Hamed BM, Elsawy M, et al. Efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: A meta-analysis with trial sequential analysis and reconstructed time-to-event data. Thromb Res. 2025;254:109476. doi:10.1016/j.thromres.2025.109476. PubMed PMID: 40957133.
- Bakht D, Arham M, Rashid Z, Amir M, Nasir Z, Naqvi MZ, et al. Reduced versus full-dose direct oral anticoagulants for venous thromboembolism in cancer patients: A systematic review and meta-analysis. EJHaem. 2025;6(5):e70155. doi:10.1002/jha2.70155. PubMed PMID: 41000253; PubMed Central PMCID: PMC12459301.
- de Lucena LA, Duarte AG, Hespanhol LC, Muniz J, Félix N, Medeiros K, et al. Reduced vs full-dose direct oral anticoagulants for extended treatment of cancer-associated venous thromboembolism: A systematic review and meta-analysis of randomized trials. J Thromb Haemost. 2025;S1538-7836(25)00645-2. doi:10.1016/j.jtha.2025.09.026. PubMed PMID: 41109354.
- Akhtar M, Nabi R, Saadia S, Ashraf DA, Hassan SM, Akhtar M, et al. Reduced-dose versus full-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: A systematic review and metaanalysis. Cardiovasc Drugs Ther. 2025. doi:10.1007/s10557-025-07759-1. PubMed PMID: 40844745.
- Bilal AR, Umar SA, Arfin SMW, Bilal AR, Sajid M, Gaba H, et al. Efficacy and safety of reduced-dose versus full-dose DOACs in extended treatment of VTE: A systematic review and meta-analysis. J Thromb Thrombolysis. 2026;59(1):55–63. doi:10.1007/s11239-025-03172-5. PubMed PMID: 40879867.
- Marik PE, Cavallazzi R. Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: A systematic review and meta-analysis. PloS One. 2015;10(11):e0143252. doi:10.1371/journal.pone.0143252. PubMed PMID: 26587983; PubMed Central PMCID: PMC4654552.
- Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, Crowther M. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2018;16(7):1288–1295. doi:10.1111/jth.14156. PubMed PMID: 29772108.
- The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415. doi:10.1056/NEJMoa1306638.
- Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–718. doi:10.1056/NEJMoa1113697.
- Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J, Baker WL. Impact of prolonged anticoagulation with rivaroxaban on provoked venous thromboembolism recurrence: IMPROVE-VTE. Am J Med. 2019;132(4):498–504. doi:10.1016/j.amjmed.2018.11.040. PubMed PMID: 30582894.
- Beckers MMJ, Schutgens REG, Prins MH, Biesma DH. Prevalence and characteristics of occult cancer in patients with venous thromboembolism. Blood. 2005;106(11):1623. doi:10.1182/blood.V106.11.1623.1623.
- Writing Committee Members; Creager MA, Barnes GD, Giri J, Mukherjee D, Jones WS, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN guideline for the evaluation and management of acute pulmonary embolism in adults: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(12):e977-e1051. doi:10.1161/CIR.0000000000001415.
- de Winter MA, Büller HR, Carrier M, Cohen AT, Hansen JB, Kaasjager KAH, et al. Recurrent venous thromboembolism and bleeding with extended anticoagulation: The VTE-PREDICT risk score. Eur Heart J. 2023;44(14):1231–1244. doi:10.1093/eurheartj/ehac776.
Language: English
Published on: Jun 1, 2026
Published by: Romanian Society of Cardiology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Mohsin Raj Mantoo, Saadat Raj Mantoo, Mir Wajid Majeed, Anushka Kulkarni, Haziq Parveez Lone, Mazin Mansoor, Ambuj Roy, published by Romanian Society of Cardiology
This work is licensed under the Creative Commons Attribution 4.0 License.